Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ferric pyrophosphate citrate - Rockwell Medical Technologies

Next Previous
Drug Profile

Ferric pyrophosphate citrate - Rockwell Medical Technologies

Alternative Names: Dialysate Triferic; FePPi dialysate - Rockwell Medical Technologies; Ferric pyrophosphate citrate injection; FPC; FPC - Rockwell Medical Technologies; Iron supplemented dialysate - Rockwell Medical Technologies; SFP; SFP - Rockwell Medical Technologies; Triferic; TRIFERIC AVNU; Triferic AVNU; Triferic dialysate; Triferic Dialysate; Triferic PD Solution; Triferic Total Parenteral Nutrition Solution; Triferic Intravenous Solution; Triferic Iron Delivery Therapy; Triferic IV Solution; Triferic Peritoneal Dialysis Solution; Triferic TPN Solution

Latest Information Update: 02 May 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ash Access Technology; Charak LLC
  • Developer Jeil Pharmaceutical; Rockwell Medical Technologies; Sun Pharmaceutical Industries; Wanbang Biopharma
  • Class Antianaemics; Diphosphates; Heavy metals
  • Mechanism of Action Iron replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Iron deficiency anaemia; Renal failure

Most Recent Events

  • 27 Apr 2023 Preregistration for Iron deficiency anaemia in Turkey (IV)
  • 27 Apr 2023 Ferric pyrophosphate citrate receives priority review status for Iron deficiency anaemia in Turkey
  • 27 Apr 2023 Rockwell Medical Technologies anticipates approval of ferric pyrophosphate citrate for the treatment of Iron deficiency anaemia in Turkey, in 2024
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top